13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Self-nanoemulsifying system improves oral absorption and enhances anti-acute myeloid leukemia activity of berberine

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Recently, we found that berberine (BBR) exerts anti-acute myeloid leukemia activity, particularly toward high-risk and relapsed/refractory acute myeloid leukemia MV4-11 cells in vitro. However, the poor water solubility and low bioavailability observed with oral BBR administration has limited its clinical use. Therefore, we design and develop a novel oil-in-water self-nanoemulsifying system for BBR (BBR SNE) to improve oral bioavailability and enhance BBR efficacy against acute myeloid leukemia by greatly improving its solubility.

          Results

          This system (size 23.50 ± 1.67 nm, zeta potential − 3.35 ± 0.03 mV) was prepared with RH40 (surfactant), 1,2-propanediol (co-surfactant), squalene (oil) and BBR using low-energy emulsification methods. The system loaded BBR successfully according to thermal gravimetric, differential scanning calorimetry, and Fourier transform infrared spectroscopy analyses. The release profile results showed that BBR SNE released BBR more slowly than BBR solution. The relative oral bioavailability of this novel system in rabbits was significantly enhanced by 3.41-fold over that of BBR. Furthermore, Caco-2 cell monolayer transport studies showed that this system could help enhance permeation and prevent efflux of BBR. Importantly, mice with BBR SNE treatment had significantly longer survival time than BBR-treated mice ( P <  0.001) in an MV4-11 engrafted leukemia murine model.

          Conclusions

          These studies confirmed that BBR SNE is a promising therapy for acute myeloid leukemia.

          Electronic supplementary material

          The online version of this article (10.1186/s12951-018-0402-x) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references46

          • Record: found
          • Abstract: found
          • Article: not found

          Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

          C Thiede (2002)
          Constitutive activation of the FLT3 receptor tyrosine kinase, either by internal tandem duplication (ITD) of the juxtamembrane region or by point mutations in the second tyrosine kinase domain (TKD), has been described in patients with acute myelogenous leukemia (AML). We analyzed the prevalence and the potential prognostic impact of FLT3 mutations in 979 AML patients. Results were correlated with cytogenetic data and the clinical response. FLT3-ITD mutations were found in 20.4% and FLT3-TKD mutations in 7.7% of the patients. Each mutation was associated with similar clinical characteristics and was more prevalent in patients with normal karyotype. Significantly more FLT3 aberrations were found in patients with FAB M5, and fewer were found in patients with FAB M2 and M6. Although less frequent in patients with cytogenetic aberrations, FLT3-ITDs were found in 13 of 42 patients with t(15;17) and in 9 of 10 patients with t(6;9). The prevalence of the ITD allele on the DNA level was heterogeneous, ranging from faint mutant bands in some patients to predominant mutant bands in others. Based on quantitative analysis, the mutant-wild-type (wt) ratio ranged from 0.03 to 32.56 (median, 0.78). Patients with a high mutant/wt ratio (ie, greater than 0.78) had significantly shorter overall and disease-free survival, whereas survival in patients with ratios below 0.78 did not differ from those without FLT3 aberrations. Multivariate analysis confirmed a high mutant/wt ratio to be a strong independent prognostic factor. Taken together, these data confirm that FLT mutations represent a common alteration in adult AML. Constitutive activation may be associated with monocytoid differentiation. A high mutant/wt ratio in ITD-positive patients appears to have a major impact on the prognostic relevance.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Therapy-related myeloid neoplasms: when genetics and environment collide

            Therapy-related myeloid neoplasms (t-MN) arise as a late effect of chemotherapy and/or radiation administered for a primary condition, typically a malignant disease, solid organ transplant or autoimmune disease. Survival is measured in months, not years, making t-MN one of the most aggressive and lethal cancers.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Berberine, an Epiphany Against Cancer

              Alkaloids are used in traditional medicine for the treatment of many diseases. These compounds are synthesized in plants as secondary metabolites and have multiple effects on cellular metabolism. Among plant derivatives with biological properties, the isoquinoline quaternary alkaloid berberine possesses a broad range of therapeutic uses against several diseases. In recent years, berberine has been reported to inhibit cell proliferation and to be cytotoxic towards cancer cells. Based on this evidence, many derivatives have been synthesized to improve berberine efficiency and selectivity; the results so far obtained on human cancer cell lines support the idea that they could be promising agents for cancer treatment. The main properties of berberine and derivatives will be illustrated.
                Bookmark

                Author and article information

                Contributors
                xqdoctor_li@163.com
                YL7618@126.com
                273659267@qq.com
                632264799@qq.com
                tzhiq009@163.com
                12479247282@qq.com
                shizhevip@126.com
                89206346@qq.com
                sunhongwu2001@163.com
                zgsllzy@163.com
                Journal
                J Nanobiotechnology
                J Nanobiotechnology
                Journal of Nanobiotechnology
                BioMed Central (London )
                1477-3155
                5 October 2018
                5 October 2018
                2018
                : 16
                : 76
                Affiliations
                [1 ]GRID grid.452210.0, Department of Hematology, , Changsha Central Hospital, ; Changsha, 410004 Hunan People’s Republic of China
                [2 ]ISNI 0000 0000 8653 0555, GRID grid.203458.8, Department of Clinical Laboratory, , The Third Affiliated Hospital, Chongqing Medical University, ; Chongqing, 401120 People’s Republic of China
                [3 ]Army Military Medical University of Chinese PLA, Chongqing, 400038 People’s Republic of China
                [4 ]Air Force Military Medical University of Chinese PLA, Xi’an, 710000 Shanxi People’s Republic of China
                [5 ]GRID grid.452210.0, Department of Pharmacy, Cancer Institute, Phase I Clinical Trial, , Changsha Central Hospital, ; Changsha, 410004 Hunan People’s Republic of China
                [6 ]ISNI 0000 0004 1803 0208, GRID grid.452708.c, Department of Hematology, , The Second Xiangya Hospital of Central South University, ; Changsha, 410008 Hunan People’s Republic of China
                Author information
                http://orcid.org/0000-0002-4318-8424
                Article
                402
                10.1186/s12951-018-0402-x
                6172716
                30290822
                f55cbee3-2577-443a-9c8d-2e90032a7415
                © The Author(s) 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 10 May 2018
                : 18 September 2018
                Categories
                Research
                Custom metadata
                © The Author(s) 2018

                Biotechnology
                berberine,self-nanoemulsifying system,acute myeloid leukemia,mv4-11,caco-2 monolayer transport

                Comments

                Comment on this article